CliffBio
small molecule

NILOTINIB D-TARTRATE

NILOTINIB D-TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameNILOTINIB D-TARTRATE
Active ingredientNILOTINIB D-TARTRATE
StrengthEQ 200MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NILOTINIB D-TARTRATE patent cliff — loss of exclusivity — | CliffBio